| Citation: |
TAN Meijuan, YANG Shijie, XU Xiequn. A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 133-142. DOI: 10.12290/xhyxzz.2024-0146
|
To review the state of research on medullary thyroid carcinoma (MTC) over the past two decades, so as to offer a quick reference for understanding the current state and future trends in this field.
A computer was employed to search the Web of Science Core Collection database for MTC-related literature (types: articles and reviews) published between 2000 and 2022. VOS viewer 1.6.18 software was utilized to create collaboration network diagrams, heat distribution diagrams for high-yielding countries(with publication volume ≥90), research institutions (with publication volume ≥60), and authors (with publication volume ≥30), and high-frequency keyword clustering network diagrams. Cite Space 5.7.R5 software was employed to conduct cluster analysis and explosive keyword detection on co-cited literature.
A total of 4866 MTC related literature (3688 articles and 918 reviews) were obtained. Although the annual publication volume fluctuated, the overall trend showed a gradual increase. The 4866 articles are from 87 countries, involving 4250 research institutions, 21 016 authors, and 963 journals. The United States (1436 articles), MD Anderson Cancer Center at the University of Texas (139 articles), and Dralle H (Department of General Surgery at Halle Wittenberg University Hospital, 61 articles) were the countries, research institutions, and authors with the highest number of publications, respectively. High frequency keywords form four clusters: RET gene expression, prognostic factors, MTC clinical management, and MTC treatment. The keywords emerging explosively in recent years were management, survival, guideline, association, etc. The key areas of focus in highly cited literature were RET proto oncogene, targeted therapy, RET gene mutation, and so on.
In the past 20 years, MTC related research has shown a gradual upward trend, with developed countries led by the United States taking a leading position in this field. The current research hotspots are the treatment, diagnosis, application of inhibitors, and exploration of the pathogenesis of MTC.
| [1] |
Mohebati A, Shaha A R. Anatomy of thyroid and parathyroid glands and neurovascular relations[J]. Clin Anat, 2012, 25(1): 19-31. DOI: 10.1002/ca.21220
|
| [2] |
Xu S J, Han Y. The overdiagnosis of thyroid micropapillary carcinoma: the rising incidence, inert biological behavior, and countermeasures[J]. J Oncol, 2021, 2021: 5544232.
|
| [3] |
Jayasinghe R, Basnayake O, Jayarajah U, et al. Management of medullary carcinoma of the thyroid: a review[J]. J Int Med Res, 2022, 50(7): 3000605221110698. DOI: 10.1177/03000605221110698
|
| [4] |
Porter A, Wong D J. Perspectives on the treatment of advanced thyroid cancer: approved therapies, resistance mechanisms, and future directions[J]. Front Oncol, 2020, 10: 592202.
|
| [5] |
Tran B X, Pham T V, Ha G H, et al. A bibliometric analysis of the global research trend in child maltreatment[J]. Int J Environ Res Public Health, 2018, 15(7): 1456. DOI: 10.3390/ijerph15071456
|
| [6] |
Zhu X Q, Hu J Q, Deng S H, et al. Bibliometric and visual analysis of research on the links between the gut microbiota and depression from 1999 to 2019[J]. Front Psychiatry, 2020, 11: 587670.
|
| [7] |
Machens A, Lorenz K, Weber F, et al. Metastatic risk profile of microscopic lymphatic and venous invasion in medullary thyroid cancer[J]. Horm Metab Res, 2021, 53(9): 588-593. DOI: 10.1055/a-1559-3424
|
| [8] |
Machens A, Lorenz K, Weber F, et al. Exceptionality of distant metastasis in node-negative hereditary and sporadic medullary thyroid cancer: lessons learned[J]. J Clin Endocrinol Metab, 2021, 106(8): e2968-e2979. DOI: 10.1210/clinem/dgab214
|
| [9] |
Elisei R, Ciampi R, Matrone A, et al. Somatic RET indels in sporadic medullary thyroid cancer: prevalence and response to selpercatinib[J]. J Clin Endocrinol Metab, 2022, 107(8): 2195-2202. DOI: 10.1210/clinem/dgac325
|
| [10] |
Prete A, Gambale C, Cappagli V, et al. Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib[J]. Eur J Endocrinol, 2022, 187(6): 905-915. DOI: 10.1530/EJE-22-0643
|
| [11] |
Guenter R, Patel Z, Chen H. Notch signaling in thyroid cancer[J]. Adv Exp Med Biol, 2021, 1287: 155-168.
|
| [12] |
Lou I, Odorico S, Yu X M, et al. Notch3 as a novel therapeutic target in metastatic medullary thyroid cancer[J]. Surgery, 2018, 163(1): 104-111. DOI: 10.1016/j.surg.2017.07.039
|
| [13] |
Jang S, Janssen A, Aburjania Z, et al. Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo[J]. Oncotarget, 2017, 8(41): 70828-70840. DOI: 10.18632/oncotarget.19993
|
| [14] |
Arighi E, Borrello M G, Sariola H. RET tyrosine kinase signaling in development and cancer[J]. Cytokine Growth Factor Rev, 2005, 16(4/5): 441-467.
|
| [15] |
de Groot J W B, Links T P, Plukker J T M, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors[J]. Endocr Rev, 2006, 27(5): 535-560. DOI: 10.1210/er.2006-0017
|
| [16] |
Wells S A, Asa S L, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma[J]. Thyroid, 2015, 25(6): 567-610. DOI: 10.1089/thy.2014.0335
|
| [17] |
Wells S A, Gosnell J E, Gagel R F, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer[J]. J Clin Oncol, 2010, 28(5): 767-772. DOI: 10.1200/JCO.2009.23.6604
|
| [18] |
Schlumberger M J, Elisei R, Bastholt L, et al. Phase Ⅱ study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer[J]. J Clin Oncol, 2009, 27(23): 3794-3801. DOI: 10.1200/JCO.2008.18.7815
|
| [19] |
Dabelić N, Jukić T, Fröbe A. Medullary thyroid cancer-feature review and update on systemic treatment[J]. Acta Clin Croat, 2020, 59(Suppl 1): 50-59.
|
| [20] |
Ali F, Neha K, Chauhan G. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers[J]. Arch Pharm Res, 2022, 45(5): 309-327. DOI: 10.1007/s12272-022-01385-3
|
| [21] |
Kloos R T, Eng C, Evans D B, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association[J]. Thyroid, 2009, 19(6): 565-612. DOI: 10.1089/thy.2008.0403
|
| [22] |
Jassal K, Ravintharan N, Prabhakaran S, et al. Preopera-tive serum calcitonin may improve initial surgery for medullary thyroid cancer in patients with indeterminate cytology[J]. ANZ J Surg, 2022, 92(6): 1428-1433. DOI: 10.1111/ans.17690
|
| [23] |
Bartz-Kurycki M A, Oluwo O E, Morris-Wiseman L F. Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis[J]. Ther Adv Endocrinol Metab, 2021, 12: 20420188211049611. DOI: 10.1177/20420188211049611
|
| [24] |
Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10, 864 patients with nodular thyroid disorders[J]. J Clin Endocrinol Metab, 2004, 89(1): 163-168. DOI: 10.1210/jc.2003-030550
|
| [25] |
Workman A D, Soylu S, Kamani D, et al. Limitations of preoperative cytology for medullary thyroid cancer: Proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgery[J]. Head Neck, 2021, 43(3): 920-927. DOI: 10.1002/hed.26550
|
| [26] |
Thomas C M, Asa S L, Ezzat S, et al. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines[J]. Curr Oncol, 2019, 26(5): 338-344. DOI: 10.3747/co.26.5539
|
| [27] |
Wong K K, Laird A M, Moubayed A, et al. How has the management of medullary thyroid carcinoma changed with the Advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals[J]. Nucl Med Commun, 2012, 33(7): 679-688. DOI: 10.1097/MNM.0b013e3283529bf7
|
| [28] |
Dudczak R, Traub-Weidinger T. PET and PET/CT in endocrine tumours[J]. Eur J Radiol, 2010, 73(3): 481-493. DOI: 10.1016/j.ejrad.2009.12.024
|
| [1] | ZHENG Wenting, ZHOU Yuyu, JIN Qiming, YUAN Yi, LIU Yanbin, MA Xiaojun, ZHOU Jiong. Focusing on the Benefits of Patient, Promoting the Sustainable Development of Medical Consortium[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1006-1010. DOI: 10.12290/xhyxzz.2024-0646 |
| [2] | YAN Xinchun, HUO Li. Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer 68Ga-NY104 PET/CT Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 911-915. DOI: 10.12290/xhyxzz.2024-0216 |
| [3] | CHEN Yuan, XU Qiang, WANG Weibin, ZHANG Taiping, GUO Junchao. Multidisciplinary Treatment of Pancreatic Cancer: Development and Experience of PUMCH[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 758-763. DOI: 10.12290/xhyxzz.2024-0281 |
| [4] | XU Dong, CHEN Jiangyun, CAI Yiyuan. Past and Present of Implementation Science (PartⅠ)—Origin and Development[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 442-449. DOI: 10.12290/xhyxzz.2024-0023 |
| [5] | ZHAO Junxian, YANG Nan, LIU Hui, LI Jun, SU Renfeng, ZHANG Juanjuan, HE Hongfeng, ZHOU Qi, TIAN Qiannan, WANG Zijun, CHEN Yaolong, WANG Xiaohui, WU Liqun, WANG Qiang. Status and Development of Health Standards in China[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1325-1329. DOI: 10.12290/xhyxzz.2023-0347 |
| [6] | WANG Qi, LUO Xufei, WANG Zijun, YANG Nan, ZHU Di, LI Zhewei, XIN Xin, YANG Zhenhua, WANG Ling, SHI Qianling, CHEN Yaolong. WHO SMART Guidelines: A New Direction for Guideline Development and Implementation[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 868-874. DOI: 10.12290/xhyxzz.2023-0274 |
| [7] | Yuan CAO, Li-ying CUI. The Development of Thrombolytic Agents[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 121-126. DOI: 10.3969/j.issn.1674-9081.20190278 |
| [8] | Chen-xi YU, Shui SUN. Roles of Long Noncoding RNAs in the Development and Progression of Osteoarthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 85-90. DOI: 10.3969/j.issn.1674-9081.20170138 |
| [9] | Enhanced Recovery Pathways: the Direction in the Future[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 553-556. DOI: 10.3969/j.issn.1674-9081.2019.06.001 |
| [10] | Hong-wei YAO, Zhong-tao ZHANG. Perspectives of the Future Development of Colorectal Surgery in China[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 90-94. DOI: 10.3969/j.issn.1674-9081.2017.03.002 |
| 1. |
李妍，韩彤昕，毛华伟. 线上与线下医学人文教学结合应用的研究与探索. 中国继续医学教育. 2025(01): 185-188 .
| |
| 2. |
李研，赵琳琳. 英美医学教育中戏剧元素的人文透视. 中国医学伦理学. 2025(03): 385-391 .
| |
| 3. |
张慧颖，王锦帆，马宇昊，何源. 新时代中国医学人文研究热点及趋势探析. 中国医学伦理学. 2025(03): 336-345 .
| |
| 4. |
王红宇，刘金强，丁俊杰，王红，孟志剑，唐聚花，张思森. 医患沟通技能培训在急重症医学住院医生规培中的应用. 中国现代医生. 2024(02): 74-76 .
| |
| 5. |
向琳，王浩辰，黄天宇，何鲲. 基于“医教研德”复合型人才培养模式口腔种植学教学改革思考与探索. 中国医药导报. 2024(04): 70-73 .
| |
| 6. |
俞婧，王瑞，武云. 基于VOSviewer的我国叙事医学相关文献的可视化分析及启示. 中国毕业后医学教育. 2024(03): 207-213 .
| |
| 7. |
余航，安琪，金李，吴远，陈涛，肖懿慧. BOPPPS教学模式融合课程思政在本科生内科学见习中的应用. 医学教育研究与实践. 2024(03): 349-354 .
| |
| 8. |
周殷华，程瑜，崔昌杰，田晓辉，符隆文，方婵，廖晓星，陈起坤. 医文融合视域下临床医学人文教学体系研究. 中国医学伦理学. 2024(07): 860-866 .
| |
| 9. |
王京，贺欢欣，董智瑞，董健，赵明东. 住培医师人文素养的培育. 中国继续医学教育. 2024(20): 186-189 .
| |
| 10. |
敖玲敏，沈菊. 中华优秀传统文化融入大学生心理健康教育的价值之维与实践之路. 黑龙江高教研究. 2024(12): 120-126 .
| |
| 11. |
王倩，巩红，刘昌，李雁，李研，辛娟，张月浪. 以临床人文岗位胜任力为导向的医学人文多元教育渠道的探索. 医学教育研究与实践. 2023(01): 68-72 .
| |
| 12. |
徐燕玲，顾漪. 临床医师医学人文认知现状调查. 中国现代医生. 2023(05): 135-138 .
| |
| 13. |
冯悦，庞维，郑丽，李胜军，孙逊，冯辉. 新医科和新文科交叉融合对免疫学创新人才培养的探索性改革. 中国免疫学杂志. 2023(06): 1203-1206 .
| |
| 14. |
柳舟，张亮，王璐，朱睿瑶，王慧娟，张静，雷佳羲，詹丽英. 重症医学科医学人文素质教育的改革与实践. 中国继续医学教育. 2023(12): 10-14 .
| |
| 15. |
阳磊，彭蓓，张婉丽. 口腔科住院医师规范化培训医学人文教育改革实践. 经济研究导刊. 2023(12): 123-125 .
| |
| 16. |
赵娟，徐斌. 进修医师自身免疫性肝炎临床带教体会. 继续医学教育. 2023(06): 129-132 .
| |
| 17. |
刘琴，何自强，骆佳佳，冯凯娜. 以提升人文关怀能力为导向的护理学导论教学模式应用研究. 沈阳医学院学报. 2023(05): 540-543 .
| |
| 18. |
谢佳君，何勇涛，黄国琼，秦宇彤，王方芳，栗昕，黄春基. 立德树人背景下医学生德育素质培养研究. 中国社会医学杂志. 2023(05): 540-543 .
| |
| 19. |
吕晓龙，严旭，章涵. 以强化人文素养为导向的全科医学生叙事医学课程模式构建. 济源职业技术学院学报. 2023(04): 33-37 .
| |
| 20. |
吕少春，宋汉君，栾海艳，何穆涵. 基于医学模拟教学的医学生临床能力培养研究. 医学教育研究与实践. 2022(03): 294-297 .
| |
| 21. |
李超. 培养高素质临床医生路径分析. 继续医学教育. 2022(04): 61-64 .
| |
| 22. |
冯矗，陈飞，张树霞，刘古月，李晓宇. 医学人文关怀教育融入外科实习的实践探索. 中医药管理杂志. 2022(11): 88-90 .
| |
| 23. |
高铭，韩涛，池靖涵，杜振兰，杨常栓，侯豫，花少栋. 创新互动式医学人文教育在儿科住院医师规范化培训中的作用研究. 中国医学伦理学. 2022(07): 806-810 .
| |
| 24. |
胡艳超，王洪涛，王怡雯，周戬平. 医学人文教育在心血管内科混合式教学中的应用. 医学教育研究与实践. 2022(05): 648-652 .
| |
| 25. |
叶榆莹. 英语电影字幕翻译对医学生人文教育的作用探究. 才智. 2022(33): 62-65 .
| |
| 26. |
陶庆才. 抗疫精神融入医学院校课程思政的研究与实践. 浙江医学教育. 2022(05): 268-270+299 .
| |
| 27. |
张宏伟，熊梓彤，林芷伊. 英国医学人文关怀及其医学教育启示. 农垦医学. 2022(06): 561-564 .
| |
| 28. |
祝贺，敖俊红，杨蓉娅，李海涛. 全媒体时代医学摄影的边界教育在皮肤病与性病科临床教学中的意义. 实用皮肤病学杂志. 2022(06): 367-369 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: